1-5 of 5
Lenka Capkova
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Circulating Plasma Cells Are the Most Powerful Prognostic Marker in Transplant Ineligible Multiple Myeloma with 2% As a New Cut-Off for Primary Plasma Cell Leukemia

Tomas Jelinek, Renata Bezděková, David Zihala, Tereza Sevcikova, Lenka Capkova, Petra Polackova, Martin Stork, Zdenka Knechtova, Ondrej Venglar, Artur Jurczyszyn, Jorge J. Castillo, Miroslav Penka, Jakub Radocha, Sabina Sevcikova, Ludek Pour, Lucie Rihova, Roman Hajek
Journal: Blood
Blood (2021) 138 (Supplement 1): 546.
https://doi.org/10.1182/blood-2021-151592
Published: 2021
Journal Articles

Follow-up Analysis of Ixazomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Routine Clinical Practice

Jiri Minarik, Jakub Radocha, Alexandra Jungova, Jan Straub, Tomas Jelinek, Tomas Pika, Ludek Pour, Petr Pavlicek, Lubica Harvanova, Lenka Capkova, Petra Krhovska, Katerina Machalkova, Pavel Jindra, Ivan Spicka, Hana Plonkova, Martin Stork, Martin Mistrik, Jaroslav Bacovsky, Vladimir Maisnar, Roman Hajek
Journal: Blood
Blood (2021) 138 (Supplement 1): 2716.
https://doi.org/10.1182/blood-2021-148836
Published: 2021
Journal Articles

Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in Czech Republic

Tereza Popkova, Ludek Pour, Ivan Spicka, Jakub Radocha, Alexandra Jungova, Jiri Minarik, Tomas Jelinek, Petr Pavlicek, Marta Krejci, Jan Straub, Vladimir Maisnar, Tereza Dekojova, Tomas Pika, Jan Soukup, Lenka Capkova, Roman Hájek
Journal: Blood
Blood (2021) 138 (Supplement 1): 4894.
https://doi.org/10.1182/blood-2021-153978
Published: 2021
Journal Articles

Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study

Roman Hajek, Prof, MD PhD, Jiri Minarik, MD PhD, Jan Straub, MD, Ludek Pour, MD, Alexandra Jungova, Jesus G. Berdeja, MD, Mario Boccadoro, Lucie Brožová, MSc, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Frits van Rhee, MD PhD, Jorge Vela-Ojeda, MD PhD, Michael A. Thompson, MD PhD FASCO, Rafat Abonour, MD, Ajai Chari, MD, Gordon Cook, MB ChB, PhD FRCP(Glas), FRCPath, Caitlin L. Costello, MD, Faith E. Davies, MD, Vania T.M. Hungria, MD PhD, Hans C. Lee, MD, Xavier Leleu, MD PhD, Noemi Puig, MD PhD, Robert M. Rifkin, MD, Evangelos Terpos, MD PhD, Saad Z. Usmani, MD FACP, Katja C. Weisel, MD, Jeffrey A. Zonder, Magda Bařinová, MSc, Matyáš Kuhn, MSc, Jiri Silar, MSc, Lenka Capkova, Kenny Galvez, MD, Jin Lu, MDProf, Tomas Skacel, MD, Jennifer Elliott, Brittany Demers, BS, BA, Dawn Marie Stull, Pharm.D., BCOP, Kaili Ren, PhD, Vladimir Maisnar, MD PhD MBA
Journal: Blood
Blood (2019) 134 (Supplement_1): 1845.
https://doi.org/10.1182/blood-2019-126606
Published: 2019
Journal Articles

Overall Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) over Lenalidomide and Dexamethasone (RD) in RRMM Patients Treated in Routine Clinical Practice: Results from the Czech Registry of Monoclonal Gammopathies (RMG)

Jiri Minarik, MD PhD, Tomas Pika, MD PhD, Jakub Radocha, Alexandra Jungova, Jan Straub, MD, Tomas Jelinek, MD, Ludek Pour, MD, Petr Pavlicek, MD, Martin Mistrik, MD PhD, Lucie Brožová, MSc, Petra Krhovska, Katerina Machalkova, Pavel Jindra, MD PhD, Ivan Spicka, MD PhD Prof, Hana Plonkova, MD, Martin Stork, MD, Jaroslav Bacovsky, Lenka Capkova, Michal Sykora, Petr Kessler, MD, Lukáš Stejskal, MD, Adriana Heindorfer, Jana Ullrychova, Tomas Skacel, MD, Vladimir Maisnar, MD PhD MBA, Roman Hajek, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3139.
https://doi.org/10.1182/blood-2019-128865
Published: 2019